Information  X 
Enter a valid email address

BioPharma Credit PLC (BPCR)

  Print   

Friday 13 May, 2022

BioPharma Credit PLC

Notice of AGM

RNS Number : 4806L
BioPharma Credit PLC
13 May 2022
 

13 May 2022

BioPharma Credit plc

(the "Company")

NOTICE OF ANNUAL GENERAL MEETING

 

Following the publication on 22 March 2022 of its Annual Financial Report for the year ended 31 December 2021, the Company announces that it will hold its Annual General Meeting ("AGM") at 1.00 p.m. on 9 June 2022 at the offices of Herbert Smith Freehills LLP, Exchange House, Primrose Street, London EC2A 2EG.

 

A copy of the Notice of the AGM is available to view on the Company's website at http://www.bpcruk.com. It has also been submitted to the National Storage Mechanism and is available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism . Copies of the Notice of the AGM have been posted or made available to the Company's Shareholders.

 

Enquiries:

BioPharma Credit plc

via Link Company Matters Limited

Company Secretary

+44 (0)1392 477 500

 

Buchanan

David Rydell / Mark Court / Jamie Hooper / Henry Wilson

+44 (0)20 7466 5000

[email protected]

 

Notes to Editors:

BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27   March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

 

LEI: 213800AV55PYXAS7SY24 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NOASFLFFDEESEDI

a d v e r t i s e m e n t